{
    "organizations": [],
    "uuid": "0536b1742c0ce6417d3b699a0d13d02fdc05844f",
    "author": "",
    "url": "https://www.reuters.com/article/brief-amarins-says-100-pct-mark-reached/brief-amarins-says-100-pct-mark-reached-on-reduce-it-cardiovascular-outcomes-study-for-estimated-onset-of-target-primary-mace-idUSFWN1RH017",
    "ord_in_thread": 0,
    "title": "BRIEF-Amarin's says 100 pct Mark reached on REDUCE-IT Cardiovascular Outcomes Study for Estimated Onset of Target Primary MACE",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4 (Reuters) - Amarin Corporation PLC:\n* IT CARDIOVASCULAR OUTCOMES STUDY REACHES 100% MARK FOR ESTIMATED ONSET OF TARGET PRIMARY MAJOR ADVERSE CARDIOVASCULAR EVENTS\n* MAINTAINS ITS GUIDANCE TO REPORT TOP-LINE RESULTS FROM STUDY BEFORE END OF Q3 2018. Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-04T12:06:00.000+03:00",
    "crawled": "2018-04-04T12:55:25.017+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "amarin",
        "corporation",
        "plc",
        "cardiovascular",
        "outcome",
        "study",
        "reach",
        "mark",
        "estimated",
        "onset",
        "target",
        "primary",
        "major",
        "adverse",
        "cardiovascular",
        "event",
        "maintains",
        "guidance",
        "report",
        "result",
        "study",
        "end",
        "q3",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}